Delineating the "galectin signature" of the tumor microenvironment

OncoImmunology

Volumn 2, Issue 4, 2013, Pages

  Compagno, Daniel ^a   Laderach, J Diego ^a   Gentilini, Lucas ^a   Jaworski, M Felipe ^a   Rabinovich, A Gabriel ^a,b  

^a Universidad de Buenos Aires   (Argentina)

^b INST DE BIOL Y MED EXPERIMENTAL   (Argentina)

Author keywords

Angiogenesis; Galectins; Gene signature; Metastasis; Prostate cancer

Indexed keywords

ANGIOGENESIS INHIBITOR; ECALECTIN; GALECTIN; GALECTIN 1; GALECTIN 12; GALECTIN 3; GALECTIN 4; GALECTIN 8; MESSENGER RNA; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CELL INVASION; CELL MIGRATION; CELLULAR IMMUNITY; DOWN REGULATION; HUMAN; HYPOXIA; KAPOSI SARCOMA; MOLECULAR MECHANICS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN CARBOHYDRATE INTERACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; STRUCTURE ANALYSIS; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; UPREGULATION;

EID: 84886945619     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.23565     Document Type: Article

References (10)

1. Rabinovich GA, Croci DO. Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer. Immunity 2012; 36:322-35; http://dx.doi.org/10.1016/j.immuni.2012.03.004
2. Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A, et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 2004; 5:241-51; http://dx.doi.org/10.1016/S1535-6108(04)00024-8
3. Juszczynski P, Ouyang J, Monti S, Rodig SJ, Takeyama K, Abramson J, et al. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci U S A 2007; 104:13134-9; http://dx.doi.org/10.1073/pnas.0706017104
4. Soldati R, Berger E, Zenclussen AC, Jorch G, Lode HN, Salatino M, et al. Neuroblastoma triggers an immunoevasive program involving galectin-1-dependent modulation of T cell and dendritic cell compartments. Int J Cancer 2012; 131:1131-41; http://dx.doi.org/10.1002/ijc.26498
5. Banh A, Zhang J, Cao H, Bouley DM, Kwok S, Kong C, et al. Tumor galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis. Cancer Res 2011; 71:4423-31; http://dx.doi.org/10.1158/0008-5472.CAN-10-4157
6. Thijssen VL, Barkan B, Shoji H, Aries IM, Mathieu V, Deltour L, et al. Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res 2010; 70:6216-24; http://dx.doi.org/10.1158/0008-5472.CAN-09-4150
7. Mathieu V, de Lassalle EM, Toelen J, Mohr T, Bellahcène A, Van Goietsenoven G, et al. Galectin-1 in melanoma biology and related neo-angiogenesis processes. J Invest Dermatol 2012; 132:2245-54; http://dx.doi.org/10.1038/jid.2012.142
8. Croci DO, Salatino M, Rubinstein N, Cerliani JP, Cavallin LE, Leung HJ, et al. Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma. J Exp Med 2012; 209:1985-2000; http://dx.doi.org/10.1084/jem.20111665
9. Laderach DJ, Gentilini LD, Giribaldi L, Delgado VC, Nugnes L, Croci DO, et al. A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease. Cancer Res 2013; 73:86-96; http://dx.doi.org/10.1158/0008-5472.CAN-12-1260
10. Karlou M, Tzelepi V, Efstathiou E. Therapeutic targeting of the prostate cancer microenvironment. Nat Rev Urol 2010; 7:494-509; http://dx.doi.org/10.1038/nrurol.2010.134